Stemline Therapeutics Inc (STML) Sees Large Increase in Short Interest

Share on StockTwits

Stemline Therapeutics Inc (NASDAQ:STML) was the target of a large growth in short interest in January. As of January 31st, there was short interest totalling 2,811,227 shares, a growth of 31.1% from the January 15th total of 2,144,312 shares. Based on an average daily trading volume, of 1,224,535 shares, the short-interest ratio is presently 2.3 days. Currently, 7.6% of the shares of the company are sold short.

Shares of NASDAQ:STML opened at $11.24 on Thursday. Stemline Therapeutics has a one year low of $7.82 and a one year high of $20.55. The firm has a market capitalization of $362.85 million, a price-to-earnings ratio of -3.82 and a beta of 1.12.

A number of research firms recently weighed in on STML. Piper Jaffray Companies reiterated an “overweight” rating on shares of Stemline Therapeutics in a research note on Wednesday, February 6th. HC Wainwright reiterated a “buy” rating and issued a $35.00 price objective on shares of Stemline Therapeutics in a research note on Friday, January 25th. ValuEngine lowered shares of Stemline Therapeutics from a “buy” rating to a “hold” rating in a research note on Thursday, January 3rd. BidaskClub upgraded shares of Stemline Therapeutics from a “sell” rating to a “hold” rating in a research note on Thursday, December 27th. Finally, Roth Capital set a $33.00 price objective on shares of Stemline Therapeutics and gave the company a “buy” rating in a research note on Sunday, December 23rd. Three investment analysts have rated the stock with a hold rating and six have issued a buy rating to the company’s stock. The company presently has an average rating of “Buy” and an average price target of $25.40.

In related news, COO Kenneth Hoberman sold 13,547 shares of Stemline Therapeutics stock in a transaction that occurred on Tuesday, January 8th. The shares were sold at an average price of $10.15, for a total value of $137,502.05. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 14.80% of the stock is currently owned by insiders.

A number of large investors have recently made changes to their positions in the business. BlackRock Inc. boosted its holdings in Stemline Therapeutics by 4.9% in the 4th quarter. BlackRock Inc. now owns 2,065,239 shares of the biopharmaceutical company’s stock valued at $19,618,000 after purchasing an additional 95,747 shares during the period. Vanguard Group Inc boosted its holdings in Stemline Therapeutics by 1.5% in the 3rd quarter. Vanguard Group Inc now owns 1,278,029 shares of the biopharmaceutical company’s stock valued at $21,215,000 after purchasing an additional 18,487 shares during the period. Vanguard Group Inc. boosted its holdings in Stemline Therapeutics by 1.5% in the 3rd quarter. Vanguard Group Inc. now owns 1,278,029 shares of the biopharmaceutical company’s stock valued at $21,215,000 after purchasing an additional 18,487 shares during the period. Nexthera Capital LP boosted its holdings in Stemline Therapeutics by 4.0% in the 3rd quarter. Nexthera Capital LP now owns 582,070 shares of the biopharmaceutical company’s stock valued at $9,662,000 after purchasing an additional 22,553 shares during the period. Finally, Northern Trust Corp boosted its holdings in Stemline Therapeutics by 12.5% in the 2nd quarter. Northern Trust Corp now owns 380,378 shares of the biopharmaceutical company’s stock valued at $6,106,000 after purchasing an additional 42,262 shares during the period. 65.39% of the stock is owned by hedge funds and other institutional investors.

WARNING: “Stemline Therapeutics Inc (STML) Sees Large Increase in Short Interest” was posted by Week Herald and is the property of of Week Herald. If you are reading this story on another publication, it was illegally copied and republished in violation of U.S. and international copyright and trademark laws. The original version of this story can be viewed at https://weekherald.com/2019/02/14/stemline-therapeutics-inc-stml-sees-large-increase-in-short-interest.html.

About Stemline Therapeutics

Stemline Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on the discovery, acquisition, development, and commercialization of proprietary oncology therapeutics in the United States and internationally. The company develops SL-401, a targeted therapy directed to the interleukin-3 receptor (IL-3R), which has completed Phase II clinical trial for patients with blastic plasmacytoid dendritic cell neoplasm; is in Phase I/II clinical trials for patients with myeloproliferative neoplasms, chronic myelomonocytic leukemia, myelofibrosis, and acute myeloid leukemia; and is in Phase I clinical trial in combination with other agents for patients with relapsed/refractory multiple myeloma.

See Also: What is the Stochastic Momentum Index (SMI)?

Receive News & Ratings for Stemline Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stemline Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply